Alzheimer's and Parkinson's Diseases Predict Different COVID-19 Outcomes: A UK Biobank Study

Area of Science:

• Neurology
• Infectious Diseases
• Epidemiology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, has led to significant mortality globally.
• Pre-existing conditions like diabetes and hypertension are known risk factors for severe COVID-19.
• The heightened vulnerability of the elderly and those with comorbidities, coupled with the prevalence of neurodegenerative diseases in aging populations, prompted this investigation.

Purpose of the Study:

• To investigate the association between neurodegenerative disorders and COVID-19 (severe acute respiratory syndrome coronavirus 2) susceptibility and mortality.
• To determine if specific neurodegenerative diseases confer differential risks for COVID-19 infection and death.

Main Methods:

• Analysis of primary health records for 13,338 UK individuals tested for COVID-19 between March and July 2020.
• Comparison of COVID-19 infection and mortality rates among individuals with and without pre-existing neurodegenerative conditions.
• Stratification of risk based on specific diagnoses, including Alzheimer's disease and Parkinson's disease.

Main Results:

• A pre-existing diagnosis of Alzheimer's disease was associated with the highest risk of COVID-19 infection and mortality in elderly individuals.
• Patients with Parkinson's disease exhibited an increased risk of SARS-CoV-2 infection but not an elevated risk of mortality from COVID-19.
• The study identified significant differences in COVID-19 outcomes based on the type of neurodegenerative disorder.

Conclusions:

• Neurodegenerative diseases have disease-specific impacts on COVID-19 susceptibility and mortality.
• Alzheimer's disease represents a significant risk factor for severe COVID-19 outcomes, particularly in the elderly.
• Further research is warranted to understand the biological mechanisms underlying these observed differences.